You have accessJournal of UrologyStem Cell Research1 Apr 2013258 CULTURING HUMAN MUSCLE PRECURSOR CELLS (MPCS) WITH XENO-FREE MEDIUM: GMP AND CLINICAL APPLICATION PREPARATION Fahd Azzabi, Souzan Salemi, Ria Tauscher, Katharina Schallmoser, Dirk Strunk, Tullio Sulser, and Daniel Eberli Fahd AzzabiFahd Azzabi Zurich, Switzerland More articles by this author , Souzan SalemiSouzan Salemi Zurich, Switzerland More articles by this author , Ria TauscherRia Tauscher Zurich, Switzerland More articles by this author , Katharina SchallmoserKatharina Schallmoser Graz, Austria More articles by this author , Dirk StrunkDirk Strunk Graz, Austria More articles by this author , Tullio SulserTullio Sulser Zurich, Switzerland More articles by this author , and Daniel EberliDaniel Eberli Zurich, Switzerland More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2013.02.1640AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Autologous cell injections are promising therapies for many diseases including urinary incontinence, where sphincter muscle damage provokes urine leakage and significantly reduces life quality. Several animal models showed that injection of precursor or stem cells leaded to the regeneration of sphincter muscle tissue. Currently, all types of cell used in these preclinical and clinical studies are expanded in xenogenic media containing fetal bovine serum (FBS). However, before precursors or stem cells can be applied clinically it is mandatory to reduce the potential immunogenic reaction and infection risk by removing any xenogenic contaminants which is required by the new regulations and good manufacturing practice for cell therapies. METHODS In this research human MPCs were expanded in xeno-free medium using pooled human platelet lysates (pHPL) or pooled human Serum (HS). We assessed the expansion potential, the differentiation by FACS, western blot and the fibre formation in vitro. Further, we assed the in vivo muscle tissue formation after injection, specific muscle expression by western blot and contractility by organ bath. Cells grown in standard FBS medium served as controls. RESULTS Our results clearly demonstrate that HS is no substitute for FBS: MPCs isolated from human biopsies were not able to expand. Using pHPL we were able to expand the MPCs while maintaining the myo-phenotype as demonstrated by FACS, WB and IHC for MyoD, desmin and MHC. Expanded MPCs gave rise to contractile muscle tissue after injection in vivo, comparable to tissues grown using cells expanded in FBS. CONCLUSIONS In conclusion, our results show that pHPL is a suitable substitute for FBS allowing the MPCs to form contractile muscle after injection. pHPL may be used to facilitate the preparation for clinical applications. © 2013 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 189Issue 4SApril 2013Page: e106 Peer Review Report Advertisement Copyright & Permissions© 2013 by American Urological Association Education and Research, Inc.MetricsAuthor Information Fahd Azzabi Zurich, Switzerland More articles by this author Souzan Salemi Zurich, Switzerland More articles by this author Ria Tauscher Zurich, Switzerland More articles by this author Katharina Schallmoser Graz, Austria More articles by this author Dirk Strunk Graz, Austria More articles by this author Tullio Sulser Zurich, Switzerland More articles by this author Daniel Eberli Zurich, Switzerland More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...
Read full abstract